Clinical trials in Lyon – page 29

1 204 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Lyon at a glance

1 204

clinical trials

Research sites7

Quick filters

1 204 trials in Lyon

Open in trial search

Drug eruption

Recruiting

Title: Study of TAR-0520 gel for skin rash (folliculitis) caused by cancer treatment with EGFR inhibitors in colorectal cancer patients

Investigational

Title: Study of TAR-0520 gel for skin rash (folliculitis) caused by cancer treatment with EGFR inhibitors in colorectal cancer patients

Investigational

France

Participants:18–64 years · 65+ years
Substances:Brimonidine Tartrate
Sponsor:Tarian Pharma

Contact Research Centre

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Cisplatin
Sponsor:Centre Leon Berard

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

Registered drugNo placebo

Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Unicancer

Contact Research Centre

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:The University Of Birmingham

Contact Research Centre

Sickle cell disease+1

Recruiting

Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

InvestigationalNo placebo

Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Etavopivat
Sponsor:Novo Nordisk A/S

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study on the Effectiveness of Cemiplimab and Drug Combination for Patients with Oligometastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on the Effectiveness of Cemiplimab and Drug Combination for Patients with Oligometastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Institut Gustave Roussy

Contact Research Centre

Breast cancer+1

Recruiting

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Jazz Pharmaceuticals Ireland Limited

Contact Research Centre

Gastrointestinal cancer metastatic

Recruiting

Chemotherapy Dose Adjustment for Gastrointestinal Cancer Patients with DPD Deficiency Using Fluorouracil, Capecitabine, and Oxaliplatin

Registered drugNo placebo

Chemotherapy Dose Adjustment for Gastrointestinal Cancer Patients with DPD Deficiency Using Fluorouracil, Capecitabine, and Oxaliplatin

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Unicancer

Contact Research Centre

Appendicitis+1

Recruiting

Study on Post-Surgery Antibiotic Use in Patients with Complicated Acute Appendicitis: Evaluating Metronidazole, Ceftriaxone, and Ofloxacin Hydrochloride

Registered drugNo placebo

Study on Post-Surgery Antibiotic Use in Patients with Complicated Acute Appendicitis: Evaluating Metronidazole, Ceftriaxone, and Ofloxacin Hydrochloride

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ceftriaxone Sodium
Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Contact Research Centre

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:Institut Gustave Roussy

Contact Research Centre

Adenocarcinoma gastric

Recruiting

Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

Registered drugNo placebo

Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:EXL01
Sponsor:Association Gercor

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

Triple-negative breast cancer treatments
Gastric and esophageal cancer therapies
Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

Novel COVID-19 intranasal vaccine development
Yellow fever vaccine studies
ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

Chronic kidney disease management
Heart failure prevention
Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Back to France All countries